Last reviewed · How we verify
NCT06710509: PROMPT-CRC
Patient Reminders Optimizing Mail-in Prevention Testing for Colorectal Cancer
NA trial testing Three Messaging Nudges in Colon Cancer Screening in 2,106 participants. Completed in 26 February 2025.
2 January 2025
Quick facts
| Lead sponsor | Emily Rosenzweig |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | screening |
| Enrollment | 2,106 |
| Start date | 5 December 2024 |
| Primary completion | 2 January 2025 |
| Estimated completion | 26 February 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Three Messaging Nudges
Conditions studied
- Colon Cancer Screening — all drugs for Colon Cancer Screening →
Sponsor
Emily Rosenzweig
Who can join
Adults 45 to 75, any sex, with Colon Cancer Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Screening is an important tool for early colorectal cancer detection, and the most recent evidence suggests that early detection significantly improves survival rates. Current medical guidelines recommend that all people aged 45 to 75 be screened regularly. However, actual rates of screening in the United States are much lower than this. Colonoscopy is the gold standard in colon cancer screening, serving as both screening and prevention. However there are many barriers to colonoscopy uptake, including lack of awareness, patient reticence, scheduling complexity, and market variation in access. Stool testing is a valuable alternative to colonoscopy for low-risk patients. Exact Sciences is the company that makes Cologuard, which is the current best-in-class stool testing for colon cancer screening. Despite being a convenient at-home screening option, patient engagement with screening via stool testing has room for improvement. Over 40% of Ascension patients who have a stool testing order placed for them never return the screening kit in the mail. A large body of research demonstrates that interventions informed by behavioral science can support patients in engaging in a variety of preventative health behaviors. Personalized nudges have proven to be among the most effective types of interventions, along with interventions aimed at helping patients overcome barriers to screening. We aim to test whether behavioral nudges can increase stool testing kit return rates.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06710509
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colon Cancer Screening
Currently open trials in the same condition.
- NCT07320989 — Impact of Chewing Gum on Bowel Preparation in Patients Undergoing Colonoscopy · NA · active not recruiting
- NCT07351019 — Colonoscopy Bowel Prep Comparison Among Diabetic Patients · Phase 4 · recruiting
Other Emily Rosenzweig trials
Trials by the same sponsor.
- NCT06640426 — Messaging Intervention to Increase Medicare Annual Wellness Visits -- The NUDGE AWV Clinical Trial · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06710509 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emily Rosenzweig
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06710509.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing